Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BKT140 + Filgrastim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BKT140 | TN14003|BL-8040|BL8040|Motixafortide | CXCR4 Inhibitor 15 | BL-8040 (BKT140) is a selective CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may lead to decreased tumor growth (PMID: 21138752). | |
Filgrastim | Neupogen | G-CSF | Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03246529 | Phase III | Filgrastim BKT140 + Filgrastim | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) | Active, not recruiting | USA | ITA | HUN | ESP | DEU | 0 |